Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Nivolumab safe and effective for cancer patients with HIV

Gobert et al. ESMO 2018, Abstract 1213P_PR.

Publish date:: October 25, 2018

Key clinical point: Patients with HIV who are treated with nivolumab, a programmed death-1 (PD-1) inhibitor, appear to have similar safety and efficacy outcomes compared with HIV-negative patients treated with the same agent.

Major finding: No immune-related adverse events or deaths due to drug toxicity occurred.

Study details: A retrospective analysis of 20 patients with HIV who received nivolumab immunotherapy.

Disclosures: Jean-Philippe Spano, principal investigator, disclosed relationships with Gilead, Roche, BMS, and others.

Read the article.

Citation:

Gobert et al. ESMO 2018, Abstract 1213P_PR.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Immuno-oncology

Lenvatinib/pembrolizumab has good activity in advanced RCC, other solid tumors,

Dual immunotherapy goes the distance in MSI-H colorectal cancer,

T-VEC plus pembrolizumab yields promising response rate in phase 2 sarcoma study,

CAR T cells produce complete responses in T-cell malignancies,

CAR T-cell therapy advances in CLL,